Journey's end: the quest for BRCA-like hereditary breast cancer genes is nearly over.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. The Great Majority of Homologous Recombination Repair-Deficient Tumors Are Accounted for by Established Causes.Frontiers in genetics · 2022
   Article
2. The ten genes for breast (and ovarian) cancer susceptibility.Nature reviews. Clinical oncology · 2021
   Article

Corrections and comments

• Comment on
  Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers.2019

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as